An end-to-end population genomics platform

From recruitment support to Exome+® sequencing to return of results, we enable you to bring the power of genomics to your communities.

A panel-grade clinical exome

The Exome+ assay delivers the benefits of a targeted panel, the breadth of a microarray, and the completeness of an exome all from one assay

Genomics research platform

The Helix platform, with its dedicated clinical and research teams, supports you in delivering actionable genetic insights and conducting large-scale genetic analyses

Sequence once, query often

Helix sequences and securely stores Exome+ data on behalf of each participant enabling flexible and on-demand access to genomic data, with the proper consent

Privacy is one of our top priorities.

We won’t share data without a participant’s permission. We pledge to uphold the highest standards of bioethics and maintain rigorous policies and procedures to keep data safe and secure.

Learn how we protect data

An all in one assay

The Exome+ assay provides a clinical exome enhanced by ~300,000 informative non-coding regions. Due to its custom design and proprietary bioinformatics solutions, it enables both clinical return of results and supports research applications with: >99.5% call rate at ≥20x depth for clinically relevant regions, accurate detection of >100 CYP2D6 star alleles, array-equivalent genome-wide imputation of tens of millions of high-confidence SNPs for discovery and polygenic risk scores, and coverage of the entire mitochondrial genome.

White papers and more

Partner with us

Helix provides the infrastructure and services to help you carry out population-scale genomic screening and research initiatives, including one of the world's largest CLIA / CAP next-generation sequencing labs. Together, we can drive earlier identification of at-risk individuals and accelerate innovative research efforts.

Learn more

*Panel-grade: defined as a ~100% call rate across every base within clinically relevant panels (offering equivalent or superior quality to clinical panels in the market).